Viatris’ Once-Monthly Copaxone Filing Imminent, Botox ‘On Track’
Recent Approval For Revance Brand Encourages Viatris On Botox
Executive Summary
Fresh from offloading almost all its interests in biosimilars to Biocon, Viatris continues to develop several follow-on products, which it hopes will add $1bn to the company’s top line by the end of the decade.
You may also be interested in...
Viatris Welcomes FDA Date On Slow-Release Copaxone Product
Viatris and Mapi have moved a step closer to realizing the US launch of their 505(b)(2) once- monthly glatiramer acetate product, a follow-on to Teva’s Copaxone treatment for multiple sclerosis.
Viatris Is ‘Not Walking Away’ From Generics
After reporting sliding sales for both generics and complex generics in Q1, Viatris has nevertheless reaffirmed its commitment to the off-patent sector, highlighting in particular a planned launch this year of its Breyna rival to Symbicort.
Momenta Sues Viatris Over Copaxone Generic – Five Years After Launch
One Copaxone (glatiramer acetate) ANDA sponsor is suing another for alleged patent infringement, with Momenta filing a lawsuit against Viatris and its partners in a US district court.